StockUK listing UK0DTFLSEDeep Value

Boiron S.A.(0DTF) Stock Analysis

EUR --+0.00%
Reward42Moderate
Risk18Low
75%Data
EUR —+0.00 (+0.00%) Previous close · LSE
Market cap 426.66M
Reward Rating42 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Rating18 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0DTF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Boiron S.A.?

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally.

AI Brief Pro

The brief on Boiron S.A.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Boiron S.A.?

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices (in vitro diagnostics), dietary supplements, herbal remedies, cosmetics, and CBD-based products. The company is listed on the LSE in UK, with a market capitalisation of 426.66M, and a P/E ratio of 0.1x.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (42)
Company Information
SectorN/A
IndustryN/A
Market Cap426.66M
Beta0.21
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.